{"nctId":"NCT00316719","briefTitle":"Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","startDateStruct":{"date":"2006-01"},"conditions":["Chronic Hepatitis B"],"count":105,"armGroups":[{"label":"Adefovir Dipivoxil (ADV)","type":"EXPERIMENTAL","interventionNames":["Drug: ADV group"]},{"label":"Lamivudine (LAM)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: LAM group"]}],"interventions":[{"name":"LAM group","otherNames":["Lamivudine"]},{"name":"ADV group","otherNames":["adefovir dipivoxil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Have compensated chronic hepatitis B.\n* Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted.\n* Ability to read, understand, and sign the informed consent.\n* Have a positive serum HBV-DNA \\>= 1,000,000 copies/mL and ALT level 50-500 U/L\n\nExclusion criteria:\n\n* Having or suspected of having liver cancer.\n* Co-infected with Hepatitis C virus (HCV) or Human Immunodeficiency virus (HIV).\n* Autoimmune hepatitis.\n* Received any previous transplantation or having a plan for any transplantation.\n* Existence of any serious complication, except hepatitis B.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"64 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52","description":"Change from baseline was the difference of the HBV DNA copy numbers (log10) in serum collected by blood draw between baseline and Week 52","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.69","spread":"1.169"},{"groupId":"OG001","value":"-3.40","spread":"1.896"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV DNA Loss (<400 Copies/mL) at Week 52","description":"The percentages of participants with an HBV DNA level in serum of less than 400 copies/mL, which is the lower limit of detection (HBV DNA loss) at Week 52","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of HBV DNA Loss (< 400 Copies/mL)","description":"Time to onset of an HBV DNA level in serum of less than 400 copies/mL was summarized using the Kaplan-Meier method. Regarding the Measured Values, the median time to onset and its upper limit for the ADV group and the upper limit of the median time to onset for the LAM group are non-estimable because they are not observed until the end of the study. The lower limit of the median time to onset for the ADV and LAM groups are 36.0 and 20.0, respectively. The median time to onset for the LAM group is 28.0","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 52","description":"Participants with loss of Hepatitis B e antigen (HBeAg) in serum collected by blood draw: Cheminoluminescent Immuno Assay (CLIA) method","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis B e Antigen/Antibody (HBeAg/Ab) Seroconversion at Week 52","description":"Participants with loss of Hepatitis B e antigen (HBeAg) and positive for anti-Hepatitis B e antibody (HBeAb) in serum collected by blood draw: CLIA method","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of HBeAg Loss","description":"Time to onset with loss of HBeAg in serum collected by blood draw was summarized using the Kaplan-Meier method.: CLIA method. Regarding the Measured Values, the median time to onset and its lower limit and its upper limit for all groups are non-estimable because they are not observed until the end of the study.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[]},{"type":"SECONDARY","title":"Time to Onset of HBeAg/Ab Seroconversion","description":"Time to onset of HBeAg/Ab seroconversion in serum collected by blood draw was summarized using the Kaplan-Meier method.: CLIA method. Regarding the Measured Values, the median time to onset and its lower limit and its upper limit for all groups are non-estimable because they are not observed until the end of the study.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis B s Antigen (HBsAg) Loss at Week 52","description":"Participants with loss of Hepatitis B s antigen (HBsAg) in serum collected by blood draw: CLIA method","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hepatitis B s Antigen/ Antibody (HBsAg/Ab) Seroconversion at Week 52","description":"Participants with loss of Hepatitis B s antigen (HBsAg) and positive for anti-Hepatitis B s antibody (HBsAb) in serum collected by blood draw: CLIA method","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Alanine Aminotransferase (ALT) Level at Week 52","description":"Summary statistics were displayed for serum ALT.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"14.72"},{"groupId":"OG001","value":"33.0","spread":"28.12"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 52","description":"ALT normalization was defined as an ALT value that was in the normal range (\\<= 45IU/L; upper limit of normal \\[ULN\\]) at Week 52 of the participants whose ALT values were abnormal (\\>45IU/L) at baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"21.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of ALT Normalization","description":"Time to onset of ALT normalization was summarized using the Kaplan-Meier method.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Emergence of Resistant Virus at Week 52","description":"Participants with resistant mutation at Week 52. LAM resistant mutation (enzyme-linked mini-sequencing assay): rtM204I/V; ADV resistant mutation (direct sequencing assay): rtN236T or rtA181T/V in HBV DNA ; rt: reverse transcriptase gene","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Diarrhea","Blood creatine phosphokinase increased","Eczema"]}}}